Table II.
Statistical analysisa | |||||
---|---|---|---|---|---|
Variable/group | Oral montelukast (Group A) (n=80) | Inhaled fluticasone propionate (Group B) (n=82) | Inhaled budesonide (Group C) (n=77) | Overall | Post-hoc test P-value |
Duration of breathing | 1.66±2.36 | 0.95±1.87 | 0.92±1.91 | P=0.038 | 0.074c |
(days) | F=3.29 | 0.064d | |||
0.994e | |||||
Number of inhalations | 0.80±1.07 | 0.47±0.90 | 0.45±0.86 | P=0.034 | 0.070c |
(time) | F=3.42 | 0.056d | |||
0.990e | |||||
Number of emergency | 0.41±0.83 | 0.18±0.47 | 0.18±0.6 | P=0.037 | 0.064c |
visits | F=3.33 | 0.070d | |||
0.994e | |||||
Daily cost of treatment | 2.11±0.53 | 1.18±0.55 | 4.24±0.68 | P<0.00001 | <0.00001c |
(yuan) | F=559.52 | <0.00001d | |||
<0.00001e | |||||
Patient compliance (percentage, %) | 87.9% | 73.2% | 70.0% | 0.017b | |
Accumulated down time | 0.91±1.38 | 0.59±1.35 | 0.52±1.14 | P=0.132 | 0.260c |
(days) | F=2.03 | 0.145d | |||
0.938e |
All data, apart from those for patient compliance (which are presented as percentages), are presented as the mean ± standard deviation.
Analysis by one-way ANOVA (for continuous variables; means ± SD) followed by Tukey's honestly significant difference test and the
Chi-squared test (for nominal data).
Group A vs. group B
Group A vs. group C
Group B vs. group C.